164 related articles for article (PubMed ID: 36423462)
1. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study.
Morford KL; Tetrault JM; Zhou B; Li F; Gleeson B; Edelman EJ; Stein MD; Barry DT; Madden L
Drug Alcohol Depend; 2022 Dec; 241():109707. PubMed ID: 36423462
[TBL] [Abstract][Full Text] [Related]
2. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.
Franklyn AM; Eibl JK; Gauthier G; Pellegrini D; Lightfoot NE; Marsh DC
Harm Reduct J; 2017 Jan; 14(1):6. PubMed ID: 28122579
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the Impact of Prescribed Versus Nonprescribed Benzodiazepine Use in Methadone Maintenance Therapy: Results From a Population-based Retrospective Cohort Study.
Eibl JK; Wilton AS; Franklyn AM; Kurdyak P; Marsh DC
J Addict Med; 2019; 13(3):182-187. PubMed ID: 30543543
[TBL] [Abstract][Full Text] [Related]
4. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care.
Taylor JL; Laks J; Christine PJ; Kehoe J; Evans J; Kim TW; Farrell NM; White CS; Weinstein ZM; Walley AY
Drug Alcohol Depend; 2022 Jul; 236():109497. PubMed ID: 35607834
[TBL] [Abstract][Full Text] [Related]
5. Three-year retention in methadone opioid agonist treatment: A survival analysis of clients by dose, area deprivation, and availability of alcohol and cannabis outlets.
Amiri S; Hirchak K; Lutz R; McDonell MG; McPherson SM; Roll JM; Amram O
Drug Alcohol Depend; 2018 Dec; 193():63-68. PubMed ID: 30340146
[TBL] [Abstract][Full Text] [Related]
6. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
7. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder.
Schiff DM; Nielsen TC; Hoeppner BB; Terplan M; Hadland SE; Bernson D; Greenfield SF; Bernstein J; Bharel M; Reddy J; Taveras EM; Kelly JF; Wilens TE
Am J Obstet Gynecol; 2021 Oct; 225(4):424.e1-424.e12. PubMed ID: 33845029
[TBL] [Abstract][Full Text] [Related]
8. Predictors of Linkage to an Opioid Treatment Program and Methadone Treatment Retention following Hospital Discharge in a Safety-Net Setting.
Tierney HR; Takimoto SW; Azari S; Steiger S; Martin M
Subst Use Misuse; 2023; 58(9):1172-1176. PubMed ID: 37194561
[No Abstract] [Full Text] [Related]
9. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
[TBL] [Abstract][Full Text] [Related]
10. Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.
Sadek J; Saunders J
BMC Psychiatry; 2022 Jul; 22(1):516. PubMed ID: 35908052
[TBL] [Abstract][Full Text] [Related]
11. Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.
Hughto JMW; Tapper A; Rapisarda SS; Stopka TJ; Palacios WR; Case P; Silcox J; Moyo P; Green TC
Subst Abuse Treat Prev Policy; 2023 May; 18(1):30. PubMed ID: 37217975
[TBL] [Abstract][Full Text] [Related]
12. Examining differences in retention on medication for opioid use disorder: An analysis of Ohio Medicaid data.
Zhang P; Tossone K; Ashmead R; Bickert T; Bailey E; Doogan NJ; Mack A; Schmidt S; Bonny AE
J Subst Abuse Treat; 2022 May; 136():108686. PubMed ID: 34953637
[TBL] [Abstract][Full Text] [Related]
13. Predictors of treatment retention and survival among methadone-maintained patients: A possible role for a functional delta opioid receptor gene variant.
Peles E; Kim Y; Sason A; Adelson M; Levran O
Drug Alcohol Depend; 2023 Sep; 250():110903. PubMed ID: 37531661
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
15. Pilot trial of gabapentin for the treatment of benzodiazepine abuse or dependence in methadone maintenance patients.
Mariani JJ; Malcolm RJ; Mamczur AK; Choi JC; Brady R; Nunes E; Levin FR
Am J Drug Alcohol Abuse; 2016 May; 42(3):333-40. PubMed ID: 26962719
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting 6-month retention among people with opioid use disorders accessing outpatient methadone maintenance therapy in Tshwane, South Africa.
Gloeck NR; Harris BN; Webb EM; Scheibe A
S Afr Med J; 2020 Dec; 111(1):68-73. PubMed ID: 33404009
[TBL] [Abstract][Full Text] [Related]
17. Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada.
Pilarinos A; Kwa Y; Joe R; Dong H; Grant C; Fast D; Buxton JA; DeBeck K
Can J Psychiatry; 2023 Feb; 68(2):89-100. PubMed ID: 36377240
[TBL] [Abstract][Full Text] [Related]
18. Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes.
Schuman-Olivier Z; Hoeppner BB; Weiss RD; Borodovsky J; Shaffer HJ; Albanese MJ
Drug Alcohol Depend; 2013 Oct; 132(3):580-6. PubMed ID: 23688843
[TBL] [Abstract][Full Text] [Related]
19. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of QTc changes among former opiate addicts since admission to methadone maintenance treatment: benzodiazepine risk.
Peles E; Linzy S; Kreek MJ; Adelson M
J Addict Med; 2013; 7(6):428-34. PubMed ID: 24145160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
